A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Journal of infectious diseases
- Publicado em
- 15 nov 2024
- Citações
- 15
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
Carol M Kao, Christina A Rostad, Lauren E Nolan, Etza Peters, Jennifer Kleinhenz, Jacob D Sherman, Ashley Tippett, J Wai Kuo Shih, Inci Yildirim, Vivien Agbakoba et al.
Descritores MeSH
- Hepatitis E
- Immunoglobulin G
- Adult
- Double-Blind Method
- Female
- Hepatitis Antibodies
- Humans
- Immunoglobulin M
- Injections, Intramuscular
- Male
Veja também
Estudos relacionados
- Safety and immunogenicity of thiomersal-free recombinant hepatitis E vaccine: A randomized, double-blind, active-controlled study
- Long-term immunity and IgG subclass response following Hepatitis E vaccination: A longitudinal cohort study in Matlab, Bangladesh
- Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate
- Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study